Cardiovascular MRI in clinical trials: expanded applications through novel surrogate endpoints

Pitcher, Alex; Ashby, Deborah; Elliott, Paul; Petersen, Steffen E
August 2011
Heart;Aug2011, Vol. 97 Issue 16, p1286
Academic Journal
Recent advances in cardiovascular magnetic resonance (CMR) now allow the accurate and reproducible measurement of many aspects of cardiac and vascular structure and function, with prognostic data emerging for several key imaging biomarkers. These biomarkers are increasingly used in the evaluation of new drugs, devices and lifestyle modifications for the prevention and treatment of cardiovascular disease. This review outlines a conceptual framework for the application of imaging biomarkers to clinical trials, highlights several important CMR techniques which are in use in randomised studies, and reviews certain aspects of trial design, conduct and interpretation in relation to the use of CMR.


Related Articles

  • Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis. Brass, S. D.; Benedict, R. H. B.; Weinstock-Guttman, B.; Munschauer, F.; Bakshi, R. // Multiple Sclerosis (13524585);Aug2006, Vol. 12 Issue 4, p437 

    Grey matter hypointensity on T2-weighted magnetic resonance imaging (MRI) scans, suggesting iron deposition, has been described in multiple sclerosis (MS) and is related to physical disability, disease course and brain atrophy. We tested the hypothesis that subcortical grey matter T2...

  • Modeling and Reconstruction of Mixed Functional and Molecular Patterns. Yue Wang; Jianhua Xuan; Srikanchana, Rujirutana; Choyke, Peter L. // International Journal of Biomedical Imaging;2006, p1 

    Functional medical imaging promises powerful tools for the visualization and elucidation of important disease-causing biological processes in living tissue. Recent research aims to dissect the distribution or expression of multiple biomarkers associated with disease progression or response,...

  • Medical Imaging in Drug Discovery, Part I. Sinskey, Anthony J.; Finkelstein, Stan N.; Cooper, Scott M. // PharmaGenomics;Mar/Apr2004, Vol. 4 Issue 3, p20 

    Reports on the role of biomarkers in drug discovery. Significance of magnetic resonance imaging (MRI) scan and computed tomography (CT) for the development of pharmaceutical products; Use of imaging technology at the molecular and single-cell levels; Role of positron emission tomography (PET)...

  • Applications of Magnetic Resonance Microscopy. Maronpot, Robert R.; Sills, Robert C.; Johnson, G. Allan // Toxicologic Pathology;Jul/Aug2004 Supplement 2, Vol. 32, p42 

    Magnetic resonance imaging (MRI) has enjoyed enormous clinical success since the first demonstration of the method more than 30 years ago. An increasing number of pharmaceutical manufacturers seeking new biomarkers for assessing drug efficacy and toxicity are turning to MRI. A specific...

  • Foreword. Croft, Barbara Y. // Disease Markers;2003/2004, Vol. 19 Issue 2/3, p47 

    Introduces articles in the June 2004 issue of a special supplement to the "Journal of Disease Markers". Role of imaging techniques in detecting markers of disease; Use of magnetic resonance spectroscopy to detect the chemical milieu of the nucleus being focused on; Optical characteristics of...

  • Simultaneous PET-MRI: a new approach for functional and morphological imaging. Judenhofer, Martin S.; Wehrl, Hans F.; Newport, Danny F.; Catana, Ciprian; Siegel, Stefan B.; Becker, Markus; Thielscher, Axel; Kneilling, Manfred; Lichy, Matthias P.; Eichner, Martin; Klingel, Karin; Reischl, Gerald; Widmaier, Stefan; Röcken, Martin; Nutt, Robert E.; Machulla, Hans-Jürgen; Uludag, Kamil; Cherry, Simon R.; Claussen, Claus D.; Pichler, Bernd J. // Nature Medicine;Apr2008, Vol. 14 Issue 4, p459 

    Noninvasive imaging at the molecular level is an emerging field in biomedical research. This paper introduces a new technology synergizing two leading imaging methodologies: positron emission tomography (PET) and magnetic resonance imaging (MRI). Although the value of PET lies in its...

  • Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival. Chen, Christina; Huang, Raymond; MacLean, Ainsley; Muzikansky, Alona; Mukundan, Srinivasan; Wen, Patrick; Norden, Andrew // Journal of Neuro-Oncology;Nov2013, Vol. 115 Issue 2, p267 

    Although bevacizumab represented an important advance in treatment of recurrent high-grade gliomas (HGG), responses occur in fewer than half of patients. There are no validated biomarkers for anti-angiogenic therapy that are available for routine clinical use. We assessed the prognostic values...

  • Preliminary Pre-Clinical Results and Overview on PET/MRI/Fluorescent Molecular Imaging. Keon Wook Kang // Open Nuclear Medicine Journal;2010 Special Issue 3, p153 

    Molecular imaging is used for earlier detection, characterization of disease and an earlier assessment of treatment efficacy through imaging molecular/cellular events in living organisms. Fluorescent materials, radioisotopes and MRI enhancers as imaging probes, are being used for optical...

  • Imaging Biomarkers of Spine Osteoarthritis. Popham, Maria; Williams, Frances M. K. // Current Rheumatology Reviews;2010, Vol. 6 Issue 4, p268 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics